These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31878968)

  • 21. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
    Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
    Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
    JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropsychological Profiles and Trajectories in Preclinical Alzheimer's Disease.
    Ho JK; Nation DA;
    J Int Neuropsychol Soc; 2018 Aug; 24(7):693-702. PubMed ID: 29706146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin-like growth factor binding protein-2 interactions with Alzheimer's disease biomarkers.
    Lane EM; Hohman TJ; Jefferson AL;
    Brain Imaging Behav; 2017 Dec; 11(6):1779-1786. PubMed ID: 27817134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.
    Malpas CB; Saling MM; Velakoulis D; Desmond P; O'Brien TJ;
    J Alzheimers Dis; 2015; 47(4):965-75. PubMed ID: 26401775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age.
    Allison SL; Jonaitis EM; Koscik RL; Hermann BP; Mueller KD; Cary RP; Ma Y; Rowley HA; Carlsson CM; Asthana S; Zetterberg H; Blennow K; Bendlin BB; Johnson SC
    Neurobiol Aging; 2021 Jun; 102():151-160. PubMed ID: 33765428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging.
    Valech N; Mollica MA; Olives J; Tort A; Fortea J; Lleo A; Belén SS; Molinuevo JL; Rami L
    J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S87-98. PubMed ID: 26445275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reference Data for Attentional, Executive, Linguistic, and Visual Processing Tests Obtained from Cognitively Healthy Individuals with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels.
    López-Martos D; Brugulat-Serrat A; Cañas-Martínez A; Canals-Gispert L; Marne P; Gramunt N; Suárez-Calvet M; Milà-Alomà M; Minguillon C; Fauria K; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL; Grau-Rivera O; Sánchez-Benavides G;
    J Alzheimers Dis; 2023; 95(1):237-249. PubMed ID: 37483000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective disruption of the cerebral neocortex in Alzheimer's disease.
    Desikan RS; Sabuncu MR; Schmansky NJ; Reuter M; Cabral HJ; Hess CP; Weiner MW; Biffi A; Anderson CD; Rosand J; Salat DH; Kemper TL; Dale AM; Sperling RA; Fischl B;
    PLoS One; 2010 Sep; 5(9):e12853. PubMed ID: 20886094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults.
    Gold BT; Zhu Z; Brown CA; Andersen AH; LaDu MJ; Tai L; Jicha GA; Kryscio RJ; Estus S; Nelson PT; Scheff SW; Abner E; Schmitt FA; Van Eldik LJ; Smith CD
    Neurobiol Aging; 2014 Oct; 35(10):2263-71. PubMed ID: 24866404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease.
    de Souza LC; Chupin M; Lamari F; Jardel C; Leclercq D; Colliot O; Lehéricy S; Dubois B; Sarazin M
    Neurobiol Aging; 2012 Jul; 33(7):1253-7. PubMed ID: 21489655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms.
    Stankeviciute L; Blackman J; Tort-Colet N; Fernández-Arcos A; Sánchez-Benavides G; Suárez-Calvet M; Iranzo Á; Molinuevo JL; Gispert JD; Coulthard E; Grau-Rivera O
    J Sleep Res; 2024 Aug; 33(4):e14108. PubMed ID: 38035770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
    Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E
    Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease.
    Körtvélyessy P; Gukasjan A; Sweeney-Reed CM; Heinze HJ; Thurner L; Bittner DM
    J Alzheimers Dis; 2015; 46(2):375-80. PubMed ID: 25777512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.